Enter multiple symbols separated by commas

Johnson & Johnson Says Will Meet 2007 Forecast

Johnson & Johnson on Monday said it will meet a prior 2007 earnings forecast despite the failure of a highly-anticipated heart device in a key study.

Although the company said it expects the impact from the failure of the so-called CoStar stent to be between 2 and 3 cents per share for 2007, it still sees itself meeting a prior forecast range for 2007 operating earnings per share of $4.02 to $4.07, company officials said on a conference call.

Johnson & Johnson said earlier that the experimental drug-coated stent failed to meet its primary goal in the study. J&J unit Conor Medical Systems also said it will discontinue sales of the CoStar stent in certain countries in Europe, Asia and Latin America -- where it is already approved.

A pivotal study compared J&J's investigational device with one already sold by Boston Scientific . Drug-coated stents are tiny wire mesh tubes used to prop open recently unclogged heart arteries and have until recently been reliable cash cows for device makers.

J&J, which said it is stopping all ongoing trials of the device, said it saw no signs of safety troubles with the CoStar stent, but it failed to prove "non-inferiority" against Boston Scientific's Taxus stent.

The company blamed the study's failure to meet its clinical goal on a problem with the dosing of paclitaxel, the drug that coats the stent. It said it will try to develop a new version of the device with a different drug, sirolimus, which is used on J&J's already marketed drug-coated stent called Cypher.

Overall rates of death, heart attack and other serious heart events were consistent with other drug-coated stents, J&J said.

The CoStar stent is one of several in a next generation of the drug-coated devices that companies and analysts hope will restart growth, which has been slumping amid safety worries.

Doctors have been switching back to cheaper bare-metal stents amid concerns of a small but serious risk of blood clots linked to the drug-coated varieties, depressing profits for device makers.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Lottery ticket

    A thief who broke into the car of a Seattle couple left behind a million-dollar lottery ticket, NBC News reports.

  • The Lamborghini SpA Urus SUV.

    There's no shortage of luxury vehicle choices, but increasingly the wealthy are opting for high-end SUVs instead of traditional models.

  • Mike Trout #27 of the Los Angeles Angels takes a picture with fans before a game with Boston Red Sox at Fenway Park on May 23, 2015 in Boston, Massachusetts.

    MLB is using digital media initiatives like Snapchat and Web video to connect with younger viewers. Is it enough?

U.S. Video